Physician profile
William Tyndall
NPI 1225133424
$18,264.58
in general payments reported to CMS, 2019-2025
13 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $13.28 · 2021: $13K · 2022: $1,629 · 2023: $1,500 · 2024: $192 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,500 · Travel and Lodging: $517 · Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $517.34 |
| Food and Beverage | $406.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corentec America INC | $9,765.49 | 2021-2022 | |
| Smith+Nephew, INC. | $4,315.10 | 2019-2024 | Pico |
| Catalyst Orthoscience | $2,918.82 | 2022-2023 | Catalyst Total Csr |
| Mid-Atlantic Surgical Systems, LLC | $821.24 | 2019-2025 | |
| Arthrex, INC. | $158.00 | 2025 | |
| Amgen INC. | $139.23 | 2024 | Prolia, Evenity |
| Medacta USA, INC. | $81.68 | 2022 | |
| Bioventus LLC | $38.41 | 2022-2025 | Durolane |
| Depuy Synthes Sales INC. | $13.33 | 2024 | Monovisc, Orthovisc |
| Stryker Corporation | $13.28 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tyndall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.